Union City, CA, United States of America

Mingzhe Ji

This inventor holds 18 USPTO granted patents and 7 published patent applications, plus 3 CIPO patents and 9 EPO patents, primarily in Antiviral Compounds. Top assignee: Gilead Sciences, Inc.. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mingzhe Ji. Retrieved from https://idiyas.com/inventor/mingzhe-ji

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 9 (Patent Applications = 9)

Average Co-Inventor Count = 5.6

ph-index = 4

Forward Citations = 57(Granted Patents)

Company Filing History:

18 out of 946

Gilead Sciences, Inc.

patents

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Antiviral Compounds

Substituted Pyrazines

Pyridones

Therapeutic Compounds

Pharmaceutical Use

Viral Infections

Polycyclic Compounds

Dipyrido

Pyrrolo

Methanopyrido

Oxazocines

Oxazepines

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12521388 - Substituted dipyrido[1,2-a:1',2′-d]pyrazines for treating viral infections (2026-01-13),

2. 11883397 - Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections (2024-01-30),

3. 11548901 - Substituted 1,4-methanopyrido[1',2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections (2023-01-10),

4. 11213523 - Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections (2022-01-04),

5. 10800772 - Therapeutic compounds (2020-10-13),

6. 10689399 - Substituted 3,4,5,6,8,10,14,14a-octahydro-2h-2,6-methanopyrido[1',2′:4,5]pyrazino[2,1-b][1,3]oxazocines and methods for treating viral infections (2020-06-23),

7. 10668064 - Polycyclic-carbamoylpyridone compounds and their pharmaceutical use (2020-06-02),

8. 10646486 - Polycyclic-carbamoylpyridone compounds and their pharmaceutical use (2020-05-12),

9. 10456395 - Substituted dipyrido[1,2-a:1',2′-d]pyrazines for treating viral infections (2019-10-29),

10. 10035809 - Substituted 2,3,4,5,7,9,13,13a-octahydro-1,5-methanopyrido[1',2′:4,5]pyrazino[1,2-a][1,3]diazepines and methods for treating viral infections (2018-07-31),

11. 9795602 - Polycyclic-carbamoylpyridone compounds and their pharmaceutical use (2017-10-24),

12. 9732092 - Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1',2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections (2017-08-15),

13. 9700554 - Polycyclic-carbamoylpyridone compounds and their pharmaceutical use (2017-07-11),

14. 9522912 - Polycyclic-carbamoylpyridone compounds and their pharmaceutical use (2016-12-20),

15. 9458159 - Substituted pyrido[1',2′:4,5]pyrazino[1,2-a]azepines for treating viral infections (2016-10-04),

Title: Innovations by Mingzhe Ji in Viral Infection Treatment

Introduction

Mingzhe Ji is a prominent inventor based in Union City, CA, who has made significant contributions to the field of pharmaceutical sciences. With a total of 17 patents to his name, Ji's work primarily focuses on developing compounds for the treatment of viral infections, particularly human immunodeficiency virus (HIV).

Latest Patents

Among his latest patents, Ji has developed substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines aimed at treating viral infections. These compounds are designed for use in the treatment of HIV infection and include stereoisomers and pharmaceutically acceptable salts. The compounds are defined by specific formulas, which detail the various components involved in their structure. Additionally, Ji has patented substituted 1,4-methanopyrido[1',2':4,5]pyrazino[1,2-a]pyrimidines, which also target HIV infections. Similar to his previous work, these compounds include stereoisomers and pharmaceutically acceptable salts, with methods for preparation and use disclosed in the patent.

Career Highlights

Mingzhe Ji is currently employed at Gilead Sciences, Inc., a leading biopharmaceutical company known for its innovative research in antiviral therapies. His work at Gilead has positioned him at the forefront of developing new treatments for viral infections, contributing to advancements in public health.

Collaborations

Ji collaborates with notable colleagues, including Hyung-Jung Pyun and Haolun Jin, who contribute to the research and development of his innovative compounds. Their teamwork enhances the potential for breakthroughs in the treatment of viral infections.

Conclusion

Mingzhe Ji's contributions to the field of antiviral research are noteworthy, with a focus on developing effective treatments for HIV. His innovative patents and collaborations reflect a commitment to advancing medical science and improving patient outcomes.

Profile summary based on public USPTO records.